

Drug Delivery in Cancer

Part I: Technologies & Markets

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is a consultant at Jain PharmaBiotech. Prof. Jain's 478 publications include 30 books (6 as editor+ 24 as author) and 50 commercial reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals.

Edited books include "Drug Delivery Systems" (1st ed Humana/Springer 2008; 2nd ed 2014, 3rd edn 2019, in preparation) and "Drug Delivery to the Central Nervous System" (Humana/Springer, 2010). As an author, his recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011; 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical industry Press 2016, 2nd ed Springer 2017), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer, 2014). He has edited "Applied Neurogenomics" (Springer 2015).

A B O U T T H I S R E P O R T

The original report on Drug Delivery in Cancer by the author was published by Decision Resources Inc in 2000 as an enlargement of the chapter on this topic in his report on Drug Delivery Technologies (1998), which was also published by Decision Resources. The second edition was published at Jain PharmaBiotech in 2003 and has been constantly updated and rewritten since then.

**November 2018 (first edition published in 2000)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Introduction to cancer therapy	21
Molecular biology of cancer	21
Cell cycle and cancer	21
<i>Apoptosis in cancer</i>	22
<i>Autophagy</i>	22
<i>Cell division and mitotic spindles</i>	23
<i>PD-1 Pathway</i>	23
<i>DNA damage, repair and cancer</i>	24
<i>Mechanism of DNA damage in Fanconi anemia leading to leukemia</i>	24
Cancer metabolism and energy status in relation to growth.....	24
<i>Amino acids and cancer</i>	24
<i>AMP-activated protein kinase</i>	25
<i>Cancer therapeutics that target metabolism.</i>	25
Cancer cell dormancy	26
<i>Dormancy and relapse in cancer</i>	26
<i>Activating dormant cancer cells for enhancing chemotherapy</i>	26
Chromosomes and cancer	27
<i>Aneuploidy</i>	27
<i>Chromosomal instability</i>	27
<i>Telomeres and cancer</i>	28
Genes and cancer	28
<i>Accumulation of random mutations</i>	29
<i>Oncogenes</i>	29
<i>Role of Bub 1 gene in cell division</i>	29
<i>Tumor Suppressor Genes</i>	30
Hallmarks of cancer.....	31
Hypoxia of cancer cells	31
Invasion and metastases	32
<i>Tumor suppressor genes and metastases</i>	34
Methylation and cancer.....	34
Nitric oxide and cancer	34
<i>Inflammation, NO and colon cancer</i>	35
<i>NO and tumor hypoxia</i>	36
<i>NO and p53 mutations</i>	36
<i>NO and matrix metalloproteinase</i>	37
<i>Role of NO in angiogenesis in cancer</i>	37
Oxidative stress and cancer.....	38
Role of platelet-derived growth factor in proliferation of cancer.....	39
RNA and cancer	39
<i>Anticancer treatments based on RNA regulation of genes</i>	39
<i>Role of microRNAs in cancer</i>	39
Stem cells and cancer.....	40
Self-sufficiency of tumor proliferation	41
Therapeutic implications of apoptosis in cancer.....	41
Tumor angiogenesis	43
<i>Pathomechanism of angiogenesis</i>	43
<i>Role of VEGF in angiogenesis</i>	45
<i>Matrix stiffness-mediated angiogenesis in tumors</i>	45
Cancer biomarkers.....	45
Molecular imaging of cancer	46
Cancer genomics.....	46
Gene expression profiling in cancer	46
Cancer proteomics	47
Limitations of genomics and proteomics for understanding cancer	47
Cancer microenvironment.....	47
Epidemiology of cancer.....	48
Current management of cancer.....	49
Anticancer drugs.....	49
<i>Limitations of cancer chemotherapy</i>	49
Biological therapies for cancer	50
Radiotherapy.....	50
<i>Brachytherapy</i>	50
Ideal anticancer agent.....	50
Surgery	50
Basics of drug delivery in cancer	51
Role of mechanical forces in tumor growth and delivery of therapy	51

Methods of assessing drug delivery in cancer	51
Positron emission tomography (PET)	51
Historical landmarks in cancer drug delivery	52
2. Innovative treatments for cancer	53
Introduction	53
Selective estrogen receptor modulators	54
Antiangiogenic strategies for cancer	55
Development of antiangiogenic therapies	55
Classification of antiangiogenic agents	56
Examples of antiangiogenic agents	57
<i>ACE-041</i>	57
<i>Angiopoietin-2 as a target</i>	57
<i>Chemotherapy at lower than maximum tolerated dose</i>	57
<i>Galectin-3 as a target for inhibiting angiogenesis</i>	58
<i>Inhibitors of endothelial proliferation</i>	58
<i>Inducers of apoptosis of endothelial cells of tumor vessels</i>	58
<i>Lodamin</i>	59
<i>Matrix metalloproteinase inhibitors</i>	59
<i>Monoclonal antibodies with vasculostatic properties</i>	60
<i>PPARα agonists</i>	61
<i>Rapalogues as antiangiogenic agents</i>	61
<i>VEGF Trap</i>	62
Agents that decrease the permeability of tumor blood vessels	62
Antiangiogenic agents in clinical trials	62
Antiangiogenic therapy resistance	63
Combination of antiangiogenic with cytotoxic therapy	63
Antiangiogenic therapy for hematological malignancies	63
Bacterial anticancer agents	64
Tumor-targeted bacteria	65
<i>Bacterial protein for targeted delivery of liposomal cancer drugs</i>	65
<i>Bacterial carriers for targeted drug delivery to brain tumors</i>	65
<i>Genetically modified bacteria as anticancer agents</i>	66
<i>Live bacteria for delivering radioactive anticancer agents</i>	67
<i>Synchronized cycles of bacterial lysis with delivery of chemotherapy</i>	67
<i>Genetically altered strains of Salmonella as anticancer drug vectors</i>	67
Inactivated but metabolically active bacteria	68
Bacterial toxins targeted to tumors	68
<i>Immunotoxins</i>	68
<i>Escherichia Coli toxins</i>	69
<i>Engineered anthrax toxin</i>	69
<i>Recombinant fusion toxins</i>	69
Type III secretion systems	71
Induction of apoptosis in cancer by bacterial proteins	71
Induction of immune response by bacteriolytic therapy	72
Epigenetic targets for anticancer therapy	72
Innovations in cell therapy for cancer	72
Stem cell transplantation for cancer	73
Cancer drug/gene delivery by mesenchymal stem cells	73
Cancer immunotherapy	74
Cytokines	74
Epigenetic modulators and cancer immunotherapies	75
STING activation and antitumor immunity	77
Cancer vaccines	77
<i>5T4 as a target for cancer immunotherapy</i>	78
<i>Adoptive cell therapy</i>	78
<i>Antigen-specific cancer vaccines</i>	81
<i>Carcinoembryonic antigen-based vaccines</i>	82
<i>Carbohydrate-based cancer vaccines</i>	82
<i>Dendritic cells for cancer vaccination</i>	82
<i>Hybrid cell vaccination</i>	84
<i>SMART vaccines</i>	85
<i>Salmonella-based oral vaccine delivery</i>	85
<i>Tumor cell vaccines</i>	85
<i>Vaccines that simultaneously target different cancer antigens</i>	86
<i>Vaccines based on multiple tumor-associated peptides</i>	86
<i>Vaccine for cancer based on antimalaria protein</i>	87
Cancer Vaccine Consortium	87
Chemoimmunotherapy	87
Concluding remarks about cancer vaccines	88
Targeted delivery of peptides to tumor-associated macrophages	88

Targeting cancer stem cells	88
Monoclonal antibodies	89
Murine MAbs	89
Humanized MAbs	89
Actions and uses of MAbs in cancer	90
<i>Anti PD-1 and anti PD-L1 MAbs</i>	91
Targeted antibody-based cancer therapy	91
<i>Antibody-cytokine fusion proteins</i>	91
<i>Antibody ARGX-115 for targeting immunosuppressive effect of Tregs</i>	91
<i>Antibody J591 for targeted delivery of anticancer therapy</i>	91
<i>Anti-Thomsen-Friedenreich antigen MAb</i>	92
<i>Combining MAbs with anti-CD55 antibody</i>	92
<i>MAbs targeted to alpha fetoprotein receptor</i>	92
<i>MAbs that target angiogenesis</i>	93
MAbs for immune activation	93
Delivery of cancer therapy with MAbs	93
Antibody-directed enzyme prodrug therapy	94
Chemically programmed antibodies	95
Combining diagnostics with therapeutics based on MAbs	95
Radiolabeled antibodies for detection and targeted therapy of cancer	95
Other innovations for administration of antibodies	98
<i>Bispecific antibodies</i>	98
<i>Trifunctional antibodies</i>	99
<i>Tetavalent bispecific antibodies</i>	99
<i>Immunotoxins</i>	100
<i>Immunoliposomes</i>	100
<i>Combined use of MAbs and cytokines</i>	100
<i>huHMFG1-huDNase I</i>	101
<i>MAbs that selectively target cancer</i>	101
G-MAB technology	102
NanoMAbs for targeting cancer	102
Advantages and limitations of MAbs for cancer therapy	103
Antibody-drug conjugates	104
<i>Kadcyla</i>	105
<i>Adcetris</i>	105
Antibody-enzyme conjugates	106
Current and future trends in antibody-based cancer drugs	106
Innovative methods of radiation delivery	106
Image-guided ultrasound technology for delivery of radiation	106
Respiratory gating technology for radiation therapy	106
Positron therapy	107
Boron neutron capture therapy	107
<i>Application of drug delivery systems to BNCP</i>	108
<i>Use of nanotechnology to enhance BNCT</i>	109
Ion channels and transporters in cancer	109
Irreversible electroporation	110
Methods to overcome multidrug resistance (MDR)	110
Mechanism of MDR	110
<i>MDR-associated protein gene</i>	111
<i>P-glycoprotein-mediated MDR</i>	111
Strategies for overcoming MDR	111
<i>Blocking the action of P-glycoprotein</i>	111
<i>Combination of targeted drugs with different specificities</i>	112
<i>Enzyme Catalyzed Therapeutic Activation</i>	112
<i>Inhibition of DNA repair</i>	112
<i>Iron chelators that overcomes resistance to chemotherapeutics</i>	113
<i>Liposome formulation of anticancer drugs</i>	113
<i>Modification of the chemical structure of the anticancer drug</i>	114
<i>Managing resistance to antiapoptotic action of anticancer agents</i>	114
<i>Modulation of SPARC expression</i>	114
<i>Nanoparticles for producing reactive oxygen species in mitochondria</i>	114
<i>Nitric oxide inducers</i>	115
<i>Proton pump inhibitors</i>	115
<i>Repression of Prohibitin1 in drug-resistant cancer cells</i>	115
<i>Targeting proteins associated with cancer stem cells</i>	115
Targeted cancer therapies	116
Targeting cellular pathways	116
Targeting antigens in virus-associated cancer	117
Targeting the IGF-I receptor	117
Targeting Mcl-1 protein	117
Targeting mitochondrial membranes	117

Targeting tumor lymphatics.....	119
<i>LyP-1 for targeting tumor lymphatics</i>	119
Targeting tyrosine kinase receptors.....	119
<i>Inhibitors of bcr-abl tyrosine kinase</i>	119
<i>Inhibition of multiple tyrosine kinases</i>	120
<i>Inhibitors of ErbB tyrosine kinase</i>	120
Targeting the Hedgehog signaling pathway	121
Targeting caspase-8.....	121
Targeting metallo drugs to tumor cells.....	122
Targeting oncogenes	122
Targeting miRNA for cancer therapeutics	123
Targeting the transferrin receptor-mediated endocytosis pathway.....	123
Targeted anticancer therapies based on the Rad51 promoter.....	123
Targeting cancer stem cells.....	123
Targeting glycolytic pathway in cancer.....	125
Targeting glycoproteins	125
<i>Tagging cancer with modified sugars</i>	126
<i>Anticancer agents based on glycobiology</i>	126
<i>Targeting cell surface glycoproteins</i>	126
<i>Biofusion for targeted cancer therapy</i>	126
Targeting knottin peptides	127
Tarveda's Pentarin platform for targeted drug conjugates	127
Enhancing the effects of radiation and chemotherapy	128
Sensitizing and enhancing agents for chemotherapy.....	128
<i>Cofactor to enhance the efficacy of chemotherapy</i>	128
<i>Enzyme-enhanced chemotherapy</i>	128
<i>Resveratrol and quercetin for cardioprotection against chemotherapy</i>	129
<i>Tesmilifene for chemosensitization</i>	129
Sensitizing agents for radiotherapy	129
<i>IPdR</i>	129
<i>Ultrasound for enhancing response to radiation</i>	130
Manipulation of tumor oxygenation	130
<i>Hypoxia-based methods to enhance chemotherapy and radiotherapy</i>	130
<i>Hyperbaric oxygen and radiation</i>	131
<i>HIF-1 antagonists to enhance radiotherapy</i>	131
<i>Nonsteroidal antiinflammatory drugs enhance tumor radiosensitivity</i>	132
<i>ONCONASE as radiosensitivity enhancer</i>	132
Hyperthermia and chemotherapy/radiation therapy.....	132
<i>Techniques for hyperthermia</i>	132
<i>Trimodality therapy: radiation, chemotherapy, and hyperthermia</i>	133
Photodynamic therapy	133
<i>Photochemical internalization</i>	136
Thermal combination with focused ultrasound for drug delivery to tumors.....	136
Novel anticancer agents	136
Anti-EphA2 antibodies	136
Antioxidants.....	137
Brostallicin	137
Agents disrupting folate metabolism.....	137
<i>Pemetrexed</i>	137
Cell cycle inhibitors	138
Cytotoxic ribonucleases	138
DNA hypomethylating agents	139
Histone-based cancer therapy	139
<i>Histone deacetylase inhibitors</i>	139
<i>Modulation of p300/CBP histone acetyltransferase activity</i>	140
<i>Simulation of endogenous histone for anticancer therapy</i>	140
HSP90 inhibitors	141
Ion channel blockers	141
<i>IOT-101</i>	141
<i>Endovion</i>	142
LPAAT-β inhibitors.....	142
Modulation of pyruvate kinase M2	142
Modulators of protein ubiquitination	142
P13-kinase inhibitors.....	143
PARP inhibitors	143
<i>Targeted destruction of BRCA2 deficient tumors by PARP inhibitors</i>	143
<i>Companies developing and commercializing PARP inhibitors</i>	144
Prodrugs.....	145
<i>Enzyme-activated prodrugs</i>	145
<i>Ascorbic acid as a prodrug for cancer</i>	145
<i>Prolarix</i>	145

Procaspase-3 activation	145
Protein kinase G activation	146
Proteasome inhibitors	146
Recombinant human insulin-like growth factor binding protein-3	146
Second generation nucleosides	147
Targeting cancer metabolism	147
Targeting topoisomerase IB	148
Telomerase inhibitors	149
Therapeutic strategies based on the P53 pathway	149
Therapeutic strategies based on molecular mechanisms	150
<i>Checkpoint activation as a strategy against cancer</i>	150
<i>Deletion-specific targeting for cancer therapy</i>	150
<i>In vivo models for molecularly anticancer drugs</i>	151
<i>Repair-blocking drugs for enhancing effect of chemotherapy</i>	151
<i>Tumor targeting fields</i>	151
<i>Targeting mTOR signaling defects</i>	152
Combining novel anticancer approaches	152
Personalized therapy of cancer	153
Challenges of cancer classification	155
Design of future cancer therapies	156
Personalized drug development in oncology	156
<i>Role of molecular imaging</i>	156
<i>Role of molecular imaging in targeted cancer therapy</i>	157
<i>Screening for personalized anticancer drugs</i>	158
<i>Targeting pathways for personalized cancer therapy</i>	158
3. Drug delivery systems for cancer	159
Introduction	159
Routes of drug delivery in cancer	159
Intravenous delivery systems for cancer therapy	160
<i>Intravenous versus oral ascorbate for treatment of cancer</i>	161
Subcutaneous injection of anticancer agents	161
Oral delivery of anticancer agents	161
<i>5-FU combined with eniluracil</i>	163
<i>Cyclin D-dependent CDK4 and CDK6 inhibitors</i>	163
<i>High dose administration of calcitriol</i>	163
<i>Oral fluoropyrimidines</i>	164
<i>Oral gefitinib vs intravenous docetaxel</i>	164
<i>Oral paclitaxel</i>	165
<i>Oral satraplatin</i>	165
<i>Oral UFT</i>	165
<i>Oral PXD101</i>	166
Transdermal drug delivery	166
<i>Delivery of the photosensitizer drug δ-amino levulinic acid</i>	166
<i>Nanoemulsion-based delivery of caffeine for skin cancer</i>	166
<i>Transdermal delivery of methotrexate</i>	167
<i>Transdermal nitroglycerine for prostate cancer</i>	167
<i>Transdermal delivery of peptide cancer vaccines</i>	167
<i>Intradermal delivery of cancer vaccines by adenoviral vectors</i>	167
Pulmonary delivery of anticancer agents	168
Regional intra-arterial delivery of chemotherapy	168
Gas embolotherapy of tumors	169
Drug delivery to lymph nodes	169
Intraperitoneal macrophages as drug delivery vehicle	170
Challenges of cancer drug delivery	170
Tumor blood vessel pore barrier to drug delivery	170
Improvement of drug transport in tumors	170
Delivery of anticancer drugs to nuclear targets	171
Innovative formulations for drug delivery in cancer	172
Cancer targeting with polymeric drugs	172
<i>Linking anticancer drugs to polyglutamate</i>	173
<i>Improving delivery of protein-polymer anticancer drugs</i>	173
Macromolecules as delivery systems for taxanes	174
Polyamine conjugates as anticancer agents	174
Bacterial vectors as drug delivery systems for anticancer drugs	174
Microparticles as therapeutic delivery systems in cancer	175
<i>Subcutaneous injection of microspheres carrying anticancer drugs</i>	175
<i>Intravascular delivery systems using microparticles</i>	176
<i>Tumor embolization with drug-eluting beads</i>	176
<i>Tumor embolization with radioactive microparticles</i>	176
<i>Microparticles heated by magnetic field</i>	177

Magnetic targeted microparticle technology.....	177
Release of drugs from biSphere by ultrasound.....	177
Release of drugs from micelles by ultrasound.....	178
Release of drugs from microcapsules by laser.....	178
Chemoembolization.....	179
Anticancer drugs bound to carbon particles.....	179
Anticancer drugs bound to protein microspheres.....	179
Nanoerythroosomes.....	179
Micronized droplets of olive oil.....	179
Nanobiotechnology-based drug delivery for cancer.....	180
Nanoparticle formulations for drug delivery in cancer.....	181
Anticancer drug particles incorporated in liposomes.....	181
Doxorubicin nanocarriers.....	183
Encapsulating drugs in hydrogel nanoparticles.....	184
Exosomes.....	184
Folate-linked nanoparticles.....	185
Lipid based nanocarriers.....	185
Micelles for drug delivery in cancer.....	185
Minicells for targeted delivery of nanoscale anticancer therapeutics.....	187
Nanobombs for cancer.....	187
Nanodiamonds for local delivery of chemotherapy at site of cancer.....	188
Nanoparticle formulation for enhancing anticancer efficacy of cisplatin.....	188
Nanoparticle formulations of paclitaxel.....	189
Nanoparticles containing albumin and antisense oligonucleotides.....	189
Nanotechnology-based non-invasive refilling of drug delivery depots.....	189
Non-aggregating nanoparticles.....	190
Pegylated nanoliposomal formulation.....	190
Perfluorocarbon nanoparticles.....	190
Polymer nanoparticles for drug delivery.....	190
Protein nanocages for penetration of airway mucous and tumors.....	191
Protosphere nanoparticle technology.....	191
Nanoparticles-based targeted delivery of therapeutics for cancer.....	192
Antiangiogenic therapy using nanoparticles.....	193
Carbon magnetic nanoparticles for targeted drug delivery in cancer.....	193
Carbon nanotubes for targeted drug delivery to cancer cells.....	194
CRLX101 for targeted anticancer drug delivery.....	194
DNA aptamer-micelle for targeted drug delivery in cancer.....	194
Fullerenes for enhancing tumor targeting by antibodies.....	195
Gold nanoparticles for targeted drug delivery in cancer.....	195
Hepatic artery infusion of LDL-DHA nanoparticles for liver cancer.....	196
Iron oxide magnetic nanoparticle formulation for drug delivery.....	197
Laser irradiation for targeted release of drugs from nanocontainers.....	197
Lipoprotein nanoparticles targeted to cancer-associated receptors.....	197
Magnetic nanoparticles for remote-controlled drug delivery to tumors.....	197
Monitoring of targeted delivery by nanoparticle-peptide conjugates.....	198
Nanobees for targeted delivery of cytolytic peptide melittin.....	198
Nanocell for targeted drug delivery to tumor.....	199
Nanodroplets for site-specific cancer treatment.....	200
Nanogel-based stealth cancer vaccine targeting macrophages.....	200
Nanoparticle-mediated targeted delivery of peptides into tumors.....	200
Nanoparticle-mediated targeting of MAPK signaling pathway.....	201
Nanoparticles for targeted delivery of concurrent chemoradiation.....	201
Nanostructured hyaluronic acid for targeted drug delivery in cancer.....	202
Nanoparticles as antibody-drug conjugates.....	202
Nanoparticle-coated peptides for tumor targeting.....	202
Nanoparticle-mediated delivery of multiple anticancer agents.....	202
Polymer nanoparticles for targeted drug delivery in cancer.....	203
Polymersomes for targeted cancer drug delivery.....	203
Targeted drug delivery with nanoparticle-aptamer bioconjugates.....	204
Targeted nanoparticles delivery of cisplatin to mitochondrial genome.....	204
Time-delayed, dual-drug nanoparticle delivery system for cancer.....	205
Dendrimers for anticancer drug delivery.....	205
Application of dendrimers in boron neutron capture therapy.....	206
Application of dendrimers in photodynamic therapy.....	207
Dendrimer-based synthetic vector for targeted cancer gene therapy.....	207
Devices for nanotechnology-based cancer therapy.....	207
Convection-enhanced delivery with nanoliposomal CPT-11.....	207
Nanocomposite devices.....	208
Nanoengineered silicon for brachytherapy.....	208
Nanosensors for targeted drug delivery in cancer.....	209
Nanoparticles combined with physical agents for tumor ablation.....	209

<i>Carbon nanotubes for laser-induced cancer destruction</i>	209
<i>Nanoparticles and thermal ablation</i>	209
<i>Nanoparticles combined with ultrasound radiation of tumors</i>	212
<i>Nanoparticles as adjuncts to photodynamic therapy of cancer</i>	212
<i>Nanoparticles for boron neutron capture therapy</i>	213
RNA nanotechnology for delivery of cancer therapeutics	213
Nanocarriers for simultaneous delivery of multiple anticancer agents.....	213
Combination delivery systems for nanoparticle penetration into tumor tissue	214
Combination of diagnostics and therapeutics for cancer	214
<i>Biomimetic nanoparticles targeted to tumors</i>	214
<i>Dendrimer nanoparticles for targeting and imaging tumors</i>	214
<i>Gold nanoparticle plus bombesin for imaging and therapy of cancer</i>	215
<i>Gold nanorods for diagnosis plus photothermal therapy of cancer</i>	215
<i>Magnetic nanoparticles for imaging as well as therapy of cancer</i>	216
<i>Nanobialys for combining MRI with delivery of anticancer agents</i>	216
<i>Nanorobotics for detection and targeted therapy of cancer</i>	216
<i>pHLIP nanotechnology for detection and targeted therapy of cancer</i>	217
<i>Polymer nanobubbles for targeted and controlled drug delivery</i>	217
<i>Radiolabeled carbon nanotubes for tumor imaging and targeting</i>	218
<i>Targeted therapy with magnetic nanomaterials guided by antibodies</i>	218
<i>Ultrasonic tumor imaging and targeted chemotherapy by nanobubbles</i>	218
<i>Future of nanobiotechnology and targeted cancer therapy</i>	219
Polyethylene glycol technology	219
Enzon's PEG technology.....	219
Debiopharm's PEG biconjugate drug delivery platform	220
Nektar PEGylation	220
PEG Intron	220
Single-chain antibody-binding protein technology	221
Vesicular systems for drug delivery in cancer	221
Liposomes for anticancer drug delivery	222
Antibody-targeted liposomes for cancer therapy	222
ALZA's Stealth liposomes	223
Boron-containing liposomes	223
DepoFoam technology	223
Hyperthermia and liposomal drug delivery	224
Liposomal doxorubicin formulation with N-octanoyl-glucosylceramide	224
Liposome-nucleic acid complexes for anticancer drug delivery	224
Non-pegylated liposomal doxorubicin	225
Tumor-selective targeted drug delivery via folate-PEG liposomes	225
Ultrasound-mediated anticancer drug release from liposomes.....	225
Companies developing liposome-based anticancer drugs.....	225
Pharmacosomes for controlled anticancer drug delivery	226
Emulsion formulations of anticancer drugs	227
Albumin-based drug carriers	227
Anticancer drugs that bind to tumors	228
Monoclonal T cell receptor technology	228
Radioactive materials for diagnosis and targeted therapy of cancer	229
Intraperitoneal vs intravenous radioimmunotherapy	229
Peptide receptor radionuclide therapy	229
Pretargeted radioimmunotherapy of cancer	229
Radiolabeled somatostatin receptor antagonists.....	230
Theophylline enhances radioiodide uptake by cancer	230
Strategies for drug delivery in cancer	230
Direct introduction of anticancer drugs into the tumor	231
<i>Injection into the tumor</i>	231
<i>Antineoplastic drug implants into tumors</i>	232
<i>Tumor necrosis therapy</i>	233
<i>Injection into the arterial blood supply of cancer</i>	233
<i>Electrochemotherapy</i>	234
<i>Pressure-induced filtration of drugs across vessels to the tumor</i>	235
Improving drug transport to tumors	235
<i>Carbohydrate-enhanced chemotherapy</i>	235
<i>Dextrans as macromolecular anticancer drug carriers</i>	236
<i>In situ production of anticancer agents in tumors</i>	236
<i>Iotophoresis for localized delivery of cancer chemotherapy</i>	236
Strategies for increasing drug penetration into solid cancers	237
Selective destruction of cancer cells	237
<i>Hyperbaric oxygen</i>	237
<i>Sphingolipids</i>	238
<i>Targeting response to transformation-induced oxidative stress</i>	238
<i>Targeting enzymes to prevent proliferation of cancer cells</i>	238

Targeted drug delivery in cancer.....	238
<i>Affibody molecules for targeted anticancer therapy</i>	239
<i>Fatty acids as targeting vectors</i>	239
<i>Genetic targeting of the kinase activity in cancer cells</i>	240
<i>Heat-activated targeted drug delivery</i>	240
<i>Novel transporters to target photosensitizers to cancer cell nuclei</i>	241
<i>Photodynamic therapy of cancer</i>	241
<i>Radionuclides delivered with receptor targeting technology</i>	242
<i>Targeting ligands specific for cancer cells</i>	242
<i>Targeting abnormal DNA in cancer cells</i>	243
<i>Targeted delivery by tumor-activated prodrug therapy</i>	243
<i>Targeting glutathione S-transferase</i>	245
<i>Targeting tumors by exploiting leaky blood vessels</i>	245
<i>Targeted drug delivery of anticancer agents with controlled activation</i>	245
<i>Targeted delivery of anticancer agents with ReCODE™ technology</i>	246
<i>Transmembrane Carrier Systems</i>	246
<i>Transferrin-oligomers as targeting carriers in anticancer drug delivery</i>	246
<i>Tumor targeting with peptides</i>	246
<i>Ultrasound and microbubbles for targeted anticancer drug delivery</i>	247
<i>Ultrasound for targeted delivery of chemotherapeutics</i>	248
<i>Vitamin B12 and folate for targeting cancer chemotherapy</i>	248
Cell-based drug delivery in cancer.....	250
<i>Red blood cells as vehicles for drug delivery</i>	250
<i>Cells as vehicles for gene delivery</i>	250
Drug delivery in relation to circadian rhythms.....	250
Implants for systemic delivery of anticancer drugs	251
<i>Drug-eluting polymer implants</i>	252
Angiogenesis and drug delivery to tumors	252
Antiangiogenesis strategies	253
<i>Targeting tumor endothelial cells</i>	253
<i>Methods for overcoming limitations of antiangiogenesis approaches</i>	254
Vascular targeting agents	254
<i>Alpha-emitting antibodies for vascular targeting</i>	255
<i>Angiolytic therapy</i>	255
<i>Anti-phosphatidylserine antibodies as VTA</i>	255
<i>Vadimezan</i>	256
<i>Cadherin inhibitors</i>	256
<i>Fosbretabulin tromethamine</i>	257
<i>Drugs to induce clotting in tumor vessels</i>	257
<i>Selective permeation of the anticancer agent into the tumor</i>	257
<i>Targeted delivery of tissue factor</i>	258
<i>Vascular targeting agents versus antiangiogenesis agents</i>	259
<i>ZD6126</i>	259
Delivery of proteins and peptides for cancer therapy	259
<i>CELLECTRA™ electroporation device</i>	260
<i>Emisphere's Eligen™ system</i>	260
<i>Diatos Peptide Vector intra-cellular/intra-nuclear delivery technology</i>	261
<i>Lytic peptides and cancer</i>	261
<i>Modification of proteins and peptides with polymers</i>	261
<i>Peptide-based targeting of cancer biomarkers for drug delivery</i>	262
<i>Peptide-cytokine complexes as vascular targeting agents</i>	262
<i>Peptide-polymer conjugates with radionuclides</i>	263
<i>Transduction of proteins in vivo</i>	263
<i>Tumor targeting by stable toxin (ST) peptides</i>	263
Image-guided personalized drug delivery in cancer	264
A computational approach to integration of drug delivery methods for cancer.....	264

4. Delivery of Biological Therapies for Cancer..... 265

Introduction	265
Antisense therapy	265
Basics of antisense approaches.....	265
Antisense cancer therapy.....	265
Mechanisms of anticancer effect of antisense oligonucleotides	266
Selected antisense drugs in development for cancer	266
<i>Antisense targeted to ribonucleotide reductase</i>	266
<i>Immune modulatory oligonucleotide</i>	267
Ribozyme therapy	267
Spiegelmers	268
Antisense drug delivery issues.....	268
Strategies to overcome delivery problems of antisense oligonucleotides.....	269
<i>Antisense delivery in microspheres</i>	269

<i>Delivery of antisense using nanoparticles</i>	269
<i>Delivery across the blood-brain barrier</i>	270
<i>Delivery of ribozymes</i>	270
<i>Iontophoretic delivery of oligonucleotides</i>	270
<i>Liposomes-mediated oligonucleotide delivery</i>	271
<i>Neugene™ antisense drugs</i>	271
<i>Oral delivery of oligonucleotides</i>	272
<i>Peptide nucleic acid delivery</i>	272
<i>Receptor-mediated endocytosis</i>	272
<i>Delivery of ribozymes</i>	273
Combination of antisense and electrochemotherapy	273
Aptamers for combined diagnosis and therapeutics of cancer	273
Antisense compounds in clinical trials	274
RNA interference	274
Basics of RNAi	274
Comparison of antisense and RNAi	275
RNAi applications in oncology	275
siRNA-based cancer immunotherapy	276
Delivery of siRNA in cancer	277
<i>Delivery of siRNA by nanoparticles</i>	277
<i>Delivery of siRNA by nanosize liposomes</i>	278
<i>Lipid nanoparticles for delivery of anticancer siRNAs</i>	279
<i>Polymer nanoparticles for targeted delivery of anticancer siRNA</i>	279
Lipophilic siRNA for targeted delivery to solid tumors	280
Companies developing cancer therapies based on antisense and RNAi	280
DNA interference	281
Cancer gene therapy	281
Basics of gene therapy	281
Strategies for cancer gene therapy	282
Gene transfer techniques as applied to cancer gene therapy	283
<i>Viral vectors</i>	283
<i>Nonviral vectors</i>	284
<i>A polymer approach to gene therapy for cancer</i>	284
Direct gene delivery to the tumor	285
<i>Injection into tumor</i>	285
<i>Reversible electroporation</i>	286
Hematopoietic gene transfer	287
<i>Genetic modification of human hematopoietic stem cells</i>	287
Gene-based strategies for immunotherapy of cancer (immunogene therapy)	288
<i>Cytokine gene therapy</i>	288
Monoclonal antibody gene transfer	291
Transfer and expression of intracellular adhesion-1 molecules	292
Other gene therapy techniques for immunotherapy of cancer	292
<i>Chemokines</i>	292
<i>Engineered viruses as anticancer immunotherapy vectors</i>	293
<i>Fas (Apo-1)</i>	293
<i>IGF (Insulin-Like Growth Factor)</i>	293
<i>Major Histocompatibility Complex (MHC) Class I</i>	293
Inhibition of immunosuppressive function	293
microRNA gene therapy	294
Delivery of toxic genes to tumor cells for eradication (molecular chemotherapy)	294
<i>Gene-directed enzyme prodrug therapy</i>	294
Combination of gene therapy with radiotherapy	295
Multipronged therapy of cancer with microencapsulated cells	296
Correction of genetic defects in cancer cells (mutation compensation)	296
Targeted gene therapy for cancer	297
<i>Transcriptional targeting for cancer gene therapy</i>	297
<i>Targeted epidermal growth factor-mediated DNA delivery</i>	297
<i>Gene-based targeted drug delivery to tumors</i>	297
<i>Targeting gene expression to hypoxic tumor cells</i>	298
<i>Targeting gene expression by progression-elevated gene-3 promoter</i>	298
<i>Targeted delivery of retroviral particles hitchhiking on T cells</i>	299
<i>Targeting tumors with genetically modified T cells</i>	299
<i>Targeting tumors by genetically engineered stem cells</i>	299
<i>Tumor-targeted gene therapy by receptor-mediated endocytosis</i>	300
<i>Targeted site-specific delivery of anticancer genes by nanoparticles</i>	300
<i>Immunolipoplex for delivery of p53 gene</i>	301
<i>Combination of electrogene and electrochemotherapy</i>	301
Virus-mediated oncolysis	301
<i>Targeted cancer treatments based on oncolytic viruses</i>	301
<i>Oncolytic gene therapy</i>	302

<i>Cancer terminator virus</i>	302
<i>Cytokine-induced killer cells for delivery of an oncolytic virus</i>	303
<i>Facilitating oncolysis by targeting innate antiviral response by HDIs</i>	303
<i>Oncolytic HSV</i>	304
<i>Oncolytic adenoviruses</i>	304
<i>Oncolytic Coxsackie virus A21</i>	306
<i>Oncolytic vesicular stomatitis virus</i>	306
<i>Oncolytic measles virus</i>	307
<i>Oncolytic paramyxovirus</i>	307
<i>Oncolytic reovirus</i>	307
<i>Oncolytic vaccinia virus</i>	308
<i>Synthetic oncolytic virus</i>	308
<i>Monitoring of viral-mediated oncolysis by PET</i>	308
<i>Companies developing oncolytic viruses</i>	309
Antiangiogenic therapy for cancer	309
Apoptotic approach to improve cancer gene therapy.....	310
Bacteria as novel anticancer gene vectors	311
Concluding remarks on cancer gene therapy	311
Cancer gene therapy companies	312
Cell therapy for cancer	314
Cellular immunotherapy for cancer.....	315
Treatments for cancer by ex vivo mobilization of immune cells	315
Granulocytes as anticancer agents	316
Neutrophil granulocytes in antibody-based immunotherapy of cancer	316
Use of hematopoietic stem cells for targeted cancer therapy	316
Cancer vaccines	317
Cell-based cancer vaccines.....	317
<i>Autologous tumor cell vaccines</i>	317
<i>Vaccines that simultaneously target different cancer antigens</i>	318
<i>Delivery systems for cell-based cancer vaccines</i>	318
<i>Intra-lymph node injections of cancer vaccine antigens</i>	319
Nucleic acid-based cancer vaccines	319
<i>Antiangiogenic DNA cancer vaccine</i>	319
<i>DNA cancer vaccines</i>	320
<i>Methods of delivery of DNA vaccines</i>	320
<i>RNA vaccines</i>	321
Viral vector-based cancer vaccines	321
Companies involved in nucleic acid-based vaccines	322
Genetically modified cancer cells vaccines	323
<i>GVAX cancer vaccines</i>	323
<i>Genetically modified dendritic cells</i>	324
Muropeptide-based cancer vaccines.....	324
5. Delivery strategies according to cancer type and location	325
Introduction	325
Bladder cancer	325
Intravesical drug delivery.....	325
Intravesical agents combined with systemic chemotherapy	325
Targeted anticancer therapy for bladder cancer	326
Prodrug EOquin for bladder cancer	326
Antisense treatment of bladder cancer.....	327
Gene therapy for bladder cancer.....	327
Brain tumors	327
Methods for evaluation of anticancer drug penetration into brain tumor	328
Innovative methods of drug delivery for glioblastoma multiforme.....	328
Delivery of anticancer drugs across the blood-brain barrier	329
<i>Anticancer agents with increased penetration of BBB</i>	329
<i>BBB disruption</i>	330
<i>Nanoparticle-based targeted delivery of chemotherapy across the BBB</i>	331
<i>Tyrosine kinase inhibitor increases topotecan penetration into CNS</i>	332
Bypassing the BBB by alternative methods of drug delivery.....	332
<i>Intranasal perillyl alcohol</i>	332
<i>Intraarterial chemotherapy</i>	333
Enhancing tumor permeability to chemotherapy	333
Local delivery of chemotherapeutic agents into the tumor	334
<i>Carmustine biodegradable polymer implants</i>	334
<i>Fibrin glue implants containing anticancer drugs</i>	335
<i>Biodegradable microspheres containing 5-FU</i>	335
<i>Magnetically controlled microspheres</i>	335
Convection-enhanced delivery	335
<i>CED for receptor-directed cytotoxin therapy</i>	335

<i>CED of topotecan</i>	336
<i>CED of a modified diphtheria toxin conjugated to transferrin</i>	336
<i>CED of nanoliposomal CPT-11</i>	337
<i>CED for delivery ¹³¹I-chTNT-1/B MAb</i>	337
Anticancer drug formulations for targeted delivery to brain tumors	337
<i>Intravenous delivery of anticancer agents bearing transferrin</i>	337
<i>Liposomes for drug delivery to brain tumors</i>	337
<i>MAbs targeted to brain tumors</i>	338
<i>Multiple targeted drugs for brain tumors</i>	338
<i>Nanoparticles for targeted drug delivery in glioblastoma multiforme</i>	339
<i>Targeted antiangiogenic/apoptotic/cytotoxic therapies</i>	340
<i>Targeted drug delivery to gliomas using cholera toxin subunit B</i>	341
Introduction of the chemotherapeutic agent into the CSF pathways	341
<i>Intraventricular chemotherapy for meningeal cancer</i>	341
<i>Intrathecal chemotherapy</i>	342
Interstitial delivery of dexamethasone for reduction of peritumor edema	342
Combination of chemotherapy with radiotherapy	342
Photodynamic therapy for chemosensitization of brain tumors	343
<i>Nanoparticles for photodynamic therapy of brain tumors</i>	343
Innovative delivery of radiotherapy to brain tumors	344
<i>GliaSite Radiation Therapy System</i>	344
<i>Boron neutron capture therapy for brain tumors</i>	344
Cell therapy for glioblastoma multiforme	344
<i>Chimeric antigen receptor T cells</i>	344
<i>Mesenchymal stem cells to deliver treatment for gliomas</i>	345
<i>Stem cell-based therapy targeting EGFR in GBM</i>	345
Gene therapy for glioblastoma multiforme	345
<i>Antiangiogenic gene therapy</i>	346
<i>Anticancer drug delivery by genetically engineered MSCs</i>	347
<i>Gene transfer to brain tumor across the BBB by nanobiotechnology</i>	347
<i>Intravenous gene delivery with nanoparticles into brain tumors</i>	347
<i>Ligand-directed delivery of dsRNA molecules targeted to EGFR</i>	348
<i>Neural stem cells for drug/gene delivery to brain tumors</i>	348
<i>Peptides targeted to glial tumor cells</i>	349
<i>RNAi gene therapy of brain cancer</i>	349
<i>Single-chain antibody-targeted adenoviral vectors</i>	350
<i>Targeting normal brain cells with an AAV vector encoding interferon-β</i>	350
<i>Treatment of medulloblastoma by suppressing genes in Shh pathway</i>	350
<i>Virus-mediated oncolytic therapy of glioblastoma multiforme</i>	351
Vaccination for glioblastoma	353
<i>Cell-based vaccines for glioblastoma</i>	353
<i>Peptide vaccines for glioblastoma</i>	354
<i>Poliovirus-based vaccine for glioblastoma</i>	354
Oncolytic viral delivery by stem cells for brain metastases of melanoma	355
Breast Cancer	355
Therapies for breast cancer involving innovative methods of drug delivery	356
Injectable biodegradable polymer delivery system for local chemotherapy	357
MammoSite brachytherapy	357
Monoclonal antibodies targeted to HER2 receptor	357
Breast cancer vaccines	358
<i>HER-2 DNA AutoVacTM vaccine</i>	358
<i>Recombinant adenoviral ErbB-2/neu vaccine</i>	359
<i>Gene vaccine for breast cancer</i>	359
<i>NeuVax</i>	360
Gene therapy for breast cancer	360
Antisense therapy for breast cancer	361
Inhibitors of growth factors FGF2 and VEGF for breast cancer	361
Targeted multi-drug delivery approach to breast cancer	361
Cancer of the cervix and the uterus	362
Gene therapy for cervical cancer	362
Delivery of chemoradiation therapy	362
Cervical cancer vaccines	362
Cancer of the liver	363
Hepatocellular carcinoma	363
Treatment of liver metastases	364
Gastrointestinal cancer	364
Colorectal cancer	364
<i>Oxaliplatin long-circulating liposomes</i>	365
<i>Perifosine</i>	365
<i>Targeted delivery of triple anticancer therapy by local patch</i>	365
Gastrointestinal stromal tumor	365

Vaccines for gastrointestinal cancer.....	366
Hematological malignancies	366
Leukemia.....	366
<i>Clofarabine</i>	367
<i>Ibrutinib</i>	367
<i>Idelalisib for CLL</i>	367
Multiple myeloma.....	368
<i>Monoclonal antibody therapy in multiple myeloma</i>	368
Non-Hodgkin's lymphoma	368
<i>Idelalisib for NHL</i>	369
<i>Pixantrone</i>	369
<i>Rituximab after autologous stem-cell transplantation</i>	369
Malignant melanoma	369
Targeted therapies for melanoma	370
Immunotherapy for malignant melanoma	370
Gene therapy for malignant melanoma	371
Nasopharyngeal carcinoma.....	373
Synergistic effect of gene therapy with 5-FU	373
Neuroblastoma	373
Genetically modified NSCs for treatment of neuroblastoma	374
Non-small cell lung cancer.....	374
Aerosol delivery of anticancer agents for lung cancer.....	375
Aerosol gene delivery for lung cancer	376
Complex nanoscale pulmonary delivery of drugs for resistant lung cancer.....	376
Intratumoral administration of anticancer drugs through a bronchoscope.....	376
Ovarian cancer.....	377
Dendritic cell vaccination for ovarian cancer	377
Gene Therapy for ovarian cancer	377
Innovative drug delivery for ovarian cancer.....	378
Intravenous ascorbate for ovarian cancer.....	378
Intraperitoneal delivery	379
Intraperitoneal hyperthermic chemotherapy in ovarian cancer	379
Modulation of protein ubiquitination	380
Targeting Notch pathway to overcome resistance to chemotherapy	380
Pancreatic cancer	380
Delivery of chemotherapy for pancreatic cancer.....	381
<i>Local drug delivery</i>	381
<i>Localized drug delivery by iontophoresis</i>	381
<i>Nanoparticle-based delivery of tumor-penetrating peptides</i>	381
<i>Targeted chemotherapy for pancreatic cancer</i>	382
<i>Transport properties of pancreatic cancer and gemcitabine delivery</i>	382
Vaccine for pancreatic cancer	383
Gene therapy for pancreatic cancer	383
<i>Correction of altered genes</i>	383
<i>Targeted gene therapy</i>	383
<i>Targeting in pancreatic adenocarcinoma with cell surface antigens</i>	384
<i>Targeted Expression of BikDD gene</i>	384
<i>Viral oncolysis in pancreatic cancer</i>	384
Prostate cancer.....	384
Alpha emitter radium-223 for targeting bone metastases in cancer	385
Brachytherapy for cancer of prostate.....	386
<i>Brachytherapy via paravertebral approach lymph node metastases</i>	386
Capridine-beta.....	386
LHRH for prostate cancer	387
<i>LHRH analogs</i>	387
<i>Histrelin implant</i>	387
Immunomodulatory drugs.....	387
MABs for prostate cancer	387
PACLIMER Microspheres.....	388
PRX302	388
Targeted therapies for prostate cancer	389
<i>Delivery of cisplatin to prostate cancer by nanoparticles</i>	389
<i>Delivery of siRNAs to prostate cancer with aptamer-siRNA chimeras</i>	389
<i>Delivery of siRNA for prostate cancer with metastases</i>	389
<i>Gold nanoparticles targeted to laminin receptor in prostate cancer</i>	389
<i>PSA-activated protoxin that kills prostate cancer</i>	390
<i>Targeted delivery of a nanoparticulate platinum prodrug</i>	390
<i>Targeting oncogene MDM2 in prostate cancer</i>	390
<i>Vascular targeting of prostate cancer</i>	391
Gene therapy for cancer of prostate	391
<i>Experimental studies</i>	391

<i>Nanoparticle-based gene therapy for prostate cancer</i>	391
<i>Tumor suppressor gene therapy in prostate cancer</i>	392
<i>Vaccines for prostate cancer</i>	392
<i>Clinical trials of gene therapy for prostate cancer</i>	393
Viral oncolysis for prostate cancer.....	394
Combined approaches	394
Combined autovaccination and hyperthermia	394
Thyroid cancer	395
6. Cancer drug delivery markets	397
Introduction	397
Global markets for drug delivery.....	397
Estimation of cancer drug delivery markets	397
<i>Methods used for market estimation</i>	397
<i>Cancer epidemiology</i>	398
<i>Cost of patient care in cancer</i>	399
Market forecasts 2017-2027	400
Cancer drug market	400
<i>Market for leukemia</i>	401
<i>Market for lymphoma</i>	401
<i>Markets for brain tumors</i>	402
<i>Market for breast cancer</i>	402
<i>Market for ovarian cancer</i>	402
Geographical distribution of cancer markets	402
Factors affecting future cancer markets	402
Market share according to cancer drug delivery technologies	403
Antiangiogenesis therapies.....	404
Antibody drug conjugates	404
Antineoplastic drug implants for systemic administration	404
Antisense therapy and RNAi	404
Cancer vaccines.....	405
Cell/gene therapy	405
Liposomes for anticancer drugs	405
Monoclonal antibodies	406
Modulators of protein ubiquitination	406
Strategic aspects of cancer drug delivery	406
Unmet needs in cancer drug delivery	407
Future of cancer drug delivery	407
Cancer drug delivery and pharmacogenomics	408
Cancer immunotherapy markets	408
Drug delivery for cancer in the postgenomic era	408
Role of nanobiotechnology in development of cancer drug delivery markets	408
Expansion of cancer drug delivery markets in developing countries	408
Drivers for the development of drug delivery technologies in cancer.....	409
7. References	411

Tables

Table 1-1: Estimated new cases of cancer in the US at most involved organs – 2017	48
Table 1-2: Historical landmarks in drug delivery for cancer	52
Table 2-1: Innovative strategies against cancer	53
Table 2-2: A classification of antiangiogenic therapies	56
Table 2-3: Selected antiangiogenic agents in development for cancer.....	62
Table 2-4: Approaches to cancer therapy based on bacteria	64
Table 2-5: Cell therapy technologies used for cancer.....	72
Table 2-6: Non-nucleic acid cancer vaccines without genetic modification	77
Table 2-7: Monoclonal antibodies for cancer approved by the FDA	89
Table 2-8: Anticancer agents linked to monoclonal antibodies	94
Table 2-9: Monoclonal antibodies in clinical trials for cancer	97
Table 2-10: Antibody drug conjugates in clinical trials for cancer	104
Table 2-11: Third generation boron delivery agents currently under investigation	108
Table 2-12: Cellular pathways as targets for anticancer therapies	116
Table 2-13: Examples of anticancer agents that target mitochondrial membranes.....	118
Table 2-14: Drugs targeting oncogenes	122
Table 2-15: PARP inhibitors for cancer therapy	144
Table 2-16: Cancer therapies based on the P53	149
Table 2-17: Promise of personalized therapy in cancer	154
Table 2-18: Companies developing personalized therapy for cancer	154

Table 3-1: Routes of drug delivery in cancer	160
Table 3-2: Systemic intravenous drug delivery systems for chemotherapy of cancer	160
Table 3-3: Approved oral chemotherapy drugs	162
Table 3-4: Microparticles as therapeutic delivery systems in cancer	175
Table 3-5: Classification of nanobiotechnology approaches to drug delivery in cancer.....	180
Table 3-6: Approved anticancer drugs using nanocarriers	181
Table 3-7: Clinical trials of anticancer drugs using nanocarriers	181
Table 3-8: Marketed preparations for liposome-based anticancer drugs	225
Table 3-9: Clinical trials of liposome-based anticancer drugs	226
Table 3-10: Strategies for drug delivery in cancer.....	230
Table 3-11: Implant systems for delivery of anticancer drugs into tumors.....	232
Table 3-12: Methods of delivery of antiangiogenesis therapies.....	253
Table 3-13: Companies developing vascular targeting agents.....	255
Table 4-1: Mechanisms of anticancer effect of antisense oligonucleotides	266
Table 4-2: Methods of delivery of oligonucleotides for cancer therapy	268
Table 4-3: Antisense oligonucleotides in clinical trials for cancer	274
Table 4-4: Companies developing antisense and RNAi therapies for cancer	280
Table 4-5: Strategies for cancer gene therapy	282
Table 4-6: Enzyme/prodrug combinations employed in suicide gene therapy.....	295
Table 4-7: Mutation compensation strategies used clinically	296
Table 4-8: Companies developing oncolytic viruses	309
Table 4-9: Companies involved in cancer gene therapy	312
Table 4-10: Cell therapy technologies used for cancer	314
Table 4-11: Companies developing nucleic acids/genetically modified cells-based cancer vaccines.....	322
Table 5-1: Innovative methods of drug delivery for glioblastoma multiforme.....	328
Table 5-2: Strategies for gene therapy of malignant brain tumors.....	345
Table 5-3: Clinical trials of oncolytic virotherapy against glioblastoma multiforme.....	353
Table 5-4: Therapies for breast cancer involving innovative methods of drug delivery	356
Table 5-5: Drug delivery for hepatocellular carcinoma	363
Table 5-6: Gene therapy for malignant melanoma	371
Table 5-7: Targeted treatment of non-small cell lung cancer	374
Table 5-8: Clinical trials of gene therapy in ovarian cancer.....	377
Table 5-9: Methods of drug delivery in pancreatic cancer	381
Table 5-10: Pharmacological strategies under investigation for cancer of the prostate.....	385
Table 5-11: Clinical trials of gene therapy for prostate cancer	393
Table 6-1: Worldwide drug delivery market growth 2017 to 2027	397
Table 6-2: Worldwide prevalence of cancer according to type of cancer 2017-2027.....	398
Table 6-3: Estimated number of cancer patients in major markets 2017-2027	399
Table 6-4: Worldwide anticancer drug sales for selected cancers from 2017 to 2027	401
Table 6-5: Geographical distribution of cancer markets 2017-2027	402
Table 6-6: Market values of cancer drug delivery technologies from 2017-2027.....	403

Figures

Figure 1-1: Structure of PD-1 pathway	23
Figure 1-2: Signaling pathway changes during adaptation of cancer cell to hypoxia.....	32
Figure 1-3: Nitric oxide: tumor enhancement or inhibition	35
Figure 1-4: Role of nitric oxide in angiogenesis.....	38
Figure 1-5: An overview of some key steps in tumor angiogenesis.	44
Figure 2-1: Targeting tumors with light-emitting engineered bacteria.....	66
Figure 2-2: Enhancing tumor-cell visibility to the immune system by viral mimicry	76
Figure 2-3: Schematic role of T helper cells in immune response to cancer	81
Figure 2-4: G-MAB™ technology	102
Figure 2-5: Antimetabolic anticancer effect of SR9243 by inhibiting Warburg effect.....	148
Figure 3-1: Cyclacel's Penetratin Transport System for delivery of drugs to targets.....	172
Figure 3-2: Micelle for drug delivery in cancer	186
Figure 3-3: Mechanism of action of Targaceutical drugs.....	240
Figure 3-4: VIADUR leuprolide acetate using DUROS implant technology	252
Figure 5-1: A concept of targeted drug delivery to GBM across the BBB.....	331
Figure 5-2: Mechanism of antitumor effects of poliovirus-based vaccine for glioblastoma.....	355
Figure 6-1: Unmet needs in cancer drug delivery	407